Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen-activated protein kinase inactivation in organ-cultured artery

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 2, 2005, Pages 327-333

  Sakamoto, Kenichi ^a   Murata, Takahisa ^a   Chuma, Hiroko ^a   Hori, Masatoshi ^a   Ozaki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Fluvastatin; Mevalonate; Organ culture; Phenotypic modulation; Smooth muscle hypertrophy

Indexed keywords

ALPHA ACTIN; BETA ACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; RAS PROTEIN;

ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL TONE; BLOOD VESSEL WALL; CELL PROLIFERATION; CHOLESTEROL METABOLISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MALE; MORPHOLOGICAL ADAPTATION; MUSCLE HYPERTROPHY; NONHUMAN; ORGAN CULTURE; PHENOTYPE; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE CONTRACTILITY; TAIL ARTERY; TUNICA MEDIA; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIES; CELL DIVISION; CHOLESTEROL; CULTURE MEDIA, SERUM-FREE; FATTY ACIDS, MONOUNSATURATED; HYPERPLASIA; INDOLES; MALE; MEVALONIC ACID; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; ORGAN CULTURE TECHNIQUES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; PROTEIN ISOPRENYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TAIL; VASOCONSTRICTION;

EID: 13244262989     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000152611.50953.e2     Document Type: Article

References (45)

1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569-1582.
2. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-213.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
6. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
7. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 1996;347:102-103.
8. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079-1082.
9. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, Egido J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 1998;83:490-500.
10. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol. 1999;10:543-559.
11. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47:648-657.
12. Veillard NR, Mach F. Statins: the new aspirin? Cell Mol Life Sci. 2002;59:1771-1786.
13. Soma MR, Donetti E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, Paoletti R. HMG CoA reductase inhibitors. In vivo effects on carotid intimai thickening in normocholesterolemic rabbits. Arterioscler Thromb. 1993;13:571-578.
14. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
15. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
16. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35-43.
17. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995;75:487-517.
18. Kashiwada K, Nishida W, Hayashi K, Ozawa K, Yamanaka Y, Saga H, Yamashita T, Tohyama M, Shimada S, Sato K, Sobue K. Coordinate expression of alpha-tropomyosin and caldesmon isoforms in association with phenotypic modulation of smooth muscle cells. J Biol Chem. 1997;272:15396-15404.
19. Hayashi K, Saga H, Chimori Y, Kimura K, Yamanaka Y, Sobue K. Differentiated phenotype of smooth muscle cells depends on signaling pathways through insulin-like growth factors and phosphatidylinositol 3-kinase. J Biol Chem. 1998;273:28860-28867.
20. Hayashi K, Takahashi M, Kimura K, Nishida W, Saga H, Sobue K. Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells. J Cell Biol. 1999;145:727-740.
21. Ozaki H, Karaki H. Organ culture as a useful method for studying the biology of blood vessels and other smooth muscle tissues. Jpn J Pharmacol. 2002;89:93-100.
22. Yamawaki H, Sato K, Hori M, Ozaki H, Nakamura S, Nakayama H, Doi K, Karaki H. Morphological and functional changes of rabbit mesenteric artery cultured with fetal bovine serum. Life Sci. 2000;67:807-820.
23. Murata T, Yamawaki H, Hori M, Sato K, Ozaki H, Karaki H. Chronic vascular toxicity of doxorubicin in an organ-cultured artery. Br J Pharmacol. 2001;132:1365-1373.
24. Dreja K, Bergdahl A, Hellstrand P. increased store-operated Ca2+ entry into contractile vascular smooth muscle following organ culture. J Vasc Res. 2001;38:324-331.
25. Yamawaki H, Sato K, Hori M, Ozaki H, Nakamura S, Nakayama H, Doi K, Karaki H. Impairment of EDR by a long-term PDGF treatment in organ-cultured rabbit mesenteric artery. Am J Physiol. 1999;277:H318-H323.
26. Murata T, Sato K, Hori M, Ozaki H, Karaki H. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem. 2002;277:44085-44092.
27. Ikeda M, Gunji Y, Yamasaki S, Takeda Y. Shiga toxin activates p38 MAP kinase through cellular Ca(2+) increase in Vero cells. FEBS Lett. 2000;485:94-98.
28. Ikeda M, Fukuda A, Takagi M, Morita M, Shimada Y. Inhibitory effect of pentalenolactone on vascular smooth muscle cell proliferation. Eur J Pharmacol. 2001;411:45-53.
29. Lindqvist A, Nordstrom I, Malmqvist U, Nordenfelt P, Hellstrand P. Long-term effects of Ca(2+) on structure and contractility of vascular smooth muscle. Am J Physiol. 1999;277:C64-C73.
30. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kipl). J Biol Chem. 1999;274:21926-21931.
31. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103:993-999.
32. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation. 2003;107:106-112.
33. Xu Q, Liu Y, Gorospe M, Udelsman R, Holbrook NJ. Acute hypertension activates mitogen-activated protein kinases in arterial wall. J Clin Invest. 1996;97:508-514.
34. Force T, Pombo CM, Avruch JA, Bonventre JV, Kyriakis JM. Stress-activated protein kinases in cardiovascular disease. Circ Res. 1996;78:947-953.
35. Izumi Y, Kim S, Namba M, Yasumoto H, Miyazaki H, Hoshiga M, Kaneda Y, Morishita R, Zhan Y, Iwao H. Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ Res. 2001;88:1120-1126.
36. Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, Iwao H. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arteriosder Thromb Vasc Biol. 2003;23:795-801.
37. Horiuchi M, Hayashida W, Akishita M, Tamura K, Daviet L, Lehtonen JY, Dzau VJ. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res. 1999;84:876-882.
38. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-1437.
39. Izumi Y, Kim S, Yoshiyama M, Izumiya Y, Yoshida K, Matsuzawa A, Koyama H, Nishizawa Y, Ichijo H, Yoshikawa J, Iwao H. Activation of apoptosis signal-regulating kinase 1 in injured artery and its critical role in neointimal hyperplasia. Circulation. 2003;108:2812-2818.
40. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev. 1979;59:1-61.
41. Casey PJ. Protein lipidation in cell signaling. Science. 1995;268:221-225.
42. Raiteri M, Arnaboldi L, McGeady P, Gelb MH, Verri D, Tagliabue C, Quarato P, Ferraboschi P, Santaniello E, Paoletti R, Fumagalli R, Corsini A. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther. 1997;281:1144-1153.
43. Stark WW Jr, Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, Pitt B, Hamilton AD, Sebti SM, Davies P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol. 1998;275:L55-L63.
44. Sozeri O, Vollmer K, Liyanage M, Frith D, Kour G, Mark GE III, Stabel S. Activation of the c-Raf protein kinase by protein kinase C phosphorylation. Oncogene. 1992;7:2259-2262.
45. Hawes BE, van Biesen T, Koch WJ, Luttrell LM, Lefkowitz RJ. Distinct pathways of Gi- and Gq-mediated mitogen-activated protein kinase activation. J Biol Chem. 1995;270:17148-17153.